ES2950461T3 - Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada - Google Patents

Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada Download PDF

Info

Publication number
ES2950461T3
ES2950461T3 ES16821453T ES16821453T ES2950461T3 ES 2950461 T3 ES2950461 T3 ES 2950461T3 ES 16821453 T ES16821453 T ES 16821453T ES 16821453 T ES16821453 T ES 16821453T ES 2950461 T3 ES2950461 T3 ES 2950461T3
Authority
ES
Spain
Prior art keywords
intraocular pressure
pyridin
therapeutic agent
acetate
ylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16821453T
Other languages
English (en)
Spanish (es)
Inventor
Tomoko Kirihara
Atsushi Shimazaki
Najam A Sharif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2950461T3 publication Critical patent/ES2950461T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ES16821453T 2015-07-09 2016-07-07 Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada Active ES2950461T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015137968 2015-07-09
PCT/JP2016/070110 WO2017006985A1 (fr) 2015-07-09 2016-07-07 Agent préventif et/ou thérapeutique contenant un composé d'acide aminoacétique pyridyle

Publications (1)

Publication Number Publication Date
ES2950461T3 true ES2950461T3 (es) 2023-10-10

Family

ID=57685038

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16821453T Active ES2950461T3 (es) 2015-07-09 2016-07-07 Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada

Country Status (6)

Country Link
US (2) US20180200239A1 (fr)
EP (1) EP3320904B1 (fr)
JP (2) JP7032134B2 (fr)
ES (1) ES2950461T3 (fr)
TW (1) TWI794140B (fr)
WO (1) WO2017006985A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019065838A1 (fr) 2017-09-29 2019-04-04 参天製薬株式会社 Médicament contenant un composé d'acide pyridylaminoacétique
EP3730143A4 (fr) 2017-12-21 2021-08-18 Santen Pharmaceutical Co., Ltd. Association de l'omidénépag
US11666563B2 (en) 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002179694A (ja) 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd リン酸エステル誘導体及び医薬組成物
DK2264009T3 (en) 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
CA2757291C (fr) 2009-03-30 2017-05-23 Ube Industries, Ltd. Composition pharmaceutique pour la prevention ou le traitement du glaucome
JP5822840B2 (ja) 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
KR101858373B1 (ko) 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3750541A1 (fr) * 2014-01-10 2020-12-16 Santen Pharmaceutical Co., Ltd Préparation pharmaceutique contenant un composé d'acide pyridylaminoacétique
AU2015205179B2 (en) 2014-01-10 2019-09-19 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylamino acetic acid compound

Also Published As

Publication number Publication date
JPWO2017006985A1 (ja) 2018-04-19
TWI794140B (zh) 2023-03-01
WO2017006985A1 (fr) 2017-01-12
EP3320904A1 (fr) 2018-05-16
EP3320904B1 (fr) 2023-07-05
US20180200239A1 (en) 2018-07-19
JP2021095406A (ja) 2021-06-24
US11331311B2 (en) 2022-05-17
US20200206200A1 (en) 2020-07-02
JP7032134B2 (ja) 2022-03-08
TW201705958A (zh) 2017-02-16
EP3320904A4 (fr) 2018-08-01

Similar Documents

Publication Publication Date Title
US11793798B2 (en) Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
ES2954412T3 (es) Solución oftálmica
US11331311B2 (en) Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
JP2015147762A (ja) ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2019081810A (ja) 水性の組成物−弐−
KR20170093816A (ko) 녹내장을 예방 또는 치료하기 위한 약물 요법